发明授权
- 专利标题： Method of increasing the bioavailability of recombinant human insulin isophane in a patient
- 专利标题（中）： 增加患者重组人胰岛素分子体生物利用度的方法
-
申请号： US12953013申请日： 2010-11-23
-
公开(公告)号： US08257735B2公开(公告)日： 2012-09-04
- 发明人: John R. Lau , W. Blair Geho
- 申请人： John R. Lau , W. Blair Geho
- 申请人地址： US OH Cleveland
- 专利权人： SDG, Inc
- 当前专利权人： SDG, Inc
- 当前专利权人地址： US OH Cleveland
- 代理机构： Riverside Law LLP
- 主分类号： A61K9/127
- IPC分类号： A61K9/127
摘要：
The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.
公开/授权文献
信息查询
